Allianz Asset Management GmbH Has $203.93 Million Stock Holdings in UiPath Inc. (NASDAQ:PATH)

Allianz Asset Management GmbH lessened its position in shares of UiPath Inc. (NASDAQ:PATH) by 2.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,876,243 shares of the healthcare company’s stock after selling 97,211 shares during the quarter. Allianz Asset Management GmbH’s holdings in UiPath were worth $203,929,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of PATH. Price T Rowe Associates Inc. MD acquired a new position in shares of UiPath during the second quarter valued at $1,521,290,000. Coatue Management LLC acquired a new position in shares of UiPath during the second quarter valued at $769,807,000. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of UiPath by 134.1% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 14,114,369 shares of the healthcare company’s stock valued at $742,557,000 after acquiring an additional 8,085,723 shares during the period. Nikko Asset Management Americas Inc. lifted its stake in shares of UiPath by 133.9% during the third quarter. Nikko Asset Management Americas Inc. now owns 14,094,071 shares of the healthcare company’s stock valued at $739,939,000 after acquiring an additional 8,069,377 shares during the period. Finally, Dragoneer Investment Group LLC acquired a new position in shares of UiPath during the second quarter valued at $374,887,000. 46.54% of the stock is currently owned by institutional investors and hedge funds.

In other UiPath news, CRO Thomas Neergaard Hansen sold 80,000 shares of the business’s stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $56.28, for a total value of $4,502,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Hitesh Ramani sold 9,464 shares of the business’s stock in a transaction dated Monday, January 3rd. The stock was sold at an average price of $43.26, for a total transaction of $409,412.64. The disclosure for this sale can be found here. Insiders have sold 616,060 shares of company stock worth $30,091,295 over the last ninety days. Insiders own 28.60% of the company’s stock.

PATH has been the topic of several research reports. Barclays cut their price target on UiPath from $61.00 to $57.00 in a research note on Wednesday. Zacks Investment Research lowered UiPath from a “hold” rating to a “sell” rating in a research note on Tuesday, December 14th. Needham & Company LLC reissued a “buy” rating and issued a $85.00 target price on shares of UiPath in a research note on Wednesday, October 6th. BMO Capital Markets cut their target price on UiPath from $70.00 to $57.00 and set a “market perform” rating on the stock in a research note on Wednesday, December 1st. Finally, Credit Suisse Group started coverage on UiPath in a research note on Tuesday, November 16th. They issued an “outperform” rating and a $75.00 target price on the stock. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $67.82.

Shares of PATH opened at $36.73 on Friday. The stock has a 50 day moving average price of $46.03 and a two-hundred day moving average price of $54.09. UiPath Inc. has a 52 week low of $35.61 and a 52 week high of $90.00.

UiPath (NASDAQ:PATH) last posted its quarterly earnings data on Wednesday, December 8th. The healthcare company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.13). The company had revenue of $220.82 million during the quarter, compared to analyst estimates of $209.23 million. The company’s quarterly revenue was up 49.9% on a year-over-year basis. Analysts expect that UiPath Inc. will post -0.79 EPS for the current year.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. It develops UiPath Studio, a platform designed for RPA developers looking to build complex process automations with built-in governance capabilities, such as robust debugging tools, application programming interface automation, wizards to automate desktop or web applications, leverage custom code, and to integrate machine learning models into production workflows.

Featured Story: Cost of Capital Explained

Want to see what other hedge funds are holding PATH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UiPath Inc. (NASDAQ:PATH).

Institutional Ownership by Quarter for UiPath (NASDAQ:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.